Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with Inceptive; Lundbeck Bocunebart Migraine Data

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

Alnylam commits up to $2B to Inceptive Nucleics forAI-driven RNAi drug discovery — $30M upfront, milestone-heavy structure. Lundbeck's bocunebart hits Phase IIb primary endpoint with 1.38-day treatmentdifference in refractory migraine. Plus Otsuka Voyxact IgAN data, Replimune's third RP1 submission, the Supreme Court's skinny label ruling, and Biogen's salanersen Breakthrough Therapy Designation.

Episode metadata supplied by the publisher feed · Published Jun 8, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with Inceptive; Lundbeck Bocunebart Migraine Data

0:00 11:21

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 11 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on June 8, 2026.

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!